Browse

Antagonistic regulation of transmembrane 4 L6 family member5 attenuates fibrotic phenotypes in CCl(4) -treated mice.

Cited 12 time in Web of Science Cited 11 time in Scopus
Authors
Kang, Minkyung; Jeong, Soo-Jin; Park, Sook Young; Lee, Hyo Jeong; Kim, Hyun Jeong; Park, Ki Hun; Ye, Sang-Kyu; Kim, Sung-Hoon; Lee, Jung Weon
Issue Date
2012-02
Publisher
Wiley-Blackwell
Citation
FEBS JOURNAL Vol.279 No.4, pp. 625-635
Keywords
복합학anti-TM4SF5CCl4-mediated liver injury
model
cytokineliver fibrosistetraspanin
Abstract
The development of liver fibrosis from chronic inflammation can involve
epithelial–mesenchymal transition (EMT). Severe liver fibrosis can progress
to cirrhosis, and further to hepatocellular carcinoma. Because the tetraspanin
transmembrane 4 L6 family member 5 (TM4SF5) induces EMT and
is highly expressed in hepatocellular carcinoma, it is of interest to investigate
whether TM4SF5 expression is correlated with EMT processes during
the development of fibrotic liver features. Using hepatic cells in vitro and a
CCl4-mediated mouse liver in vivo model, we examined whether TM4SF5 is
expressed during liver fibrosis mediated by CCl4 administration and
whether treatment with anti-TM4SF5 reagent blocks the fibrotic liver features.
Here, we found that TM4SF5 expression was induced by the transforming
growth factor (TGF)b1 and epidermal growth factor signaling
pathways in hepatocytes in vitro. In the CCl4-mediated mouse liver model,
TM4SF5 was expressed during the liver fibrosis mediated by CCl4 administration
and correlated with a-smooth muscle actin expression, collagen I
deposition, and TGFb1 and epidermal growth factor receptor signaling
activation in fibrotic septa regions. Interestingly, treatment with anti-
TM4SF5 reagent blocked the TM4SF5-mediated liver fibrotic features: the
formation of fibrotic septa with a-smooth muscle actin expression and collagen
I deposition was attenuated by treatment with anti-TM4SF5 reagent.
These results suggest that TM4SF5 expression mediated by TGFb1 and
growth factor can facilitate fibrotic processes during chronic liver injuries.
TM4SF5 is thus a candidate target for prevention of liver fibrosis following
chronic liver injury.
ISSN
1742-464X
Language
English
URI
http://hdl.handle.net/10371/82071
DOI
https://doi.org/10.1111/j.1742-4658.2011.08452.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Pharmacy (약학대학)Dept. of Pharmacy (약학과)Journal Papers (저널논문_약학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse